The treatment of chronic heart failure due to left ventricular systolic dysfunction

Clinical Medicine

Volumn 4, Issue 1, 2004, Pages 18-22

  Gardner, Roy S ^a   McDonagh, Ta ^b  

^a MONKLANDS HOSPITAL   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ALLOPURINOL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; NITRATE; SPIRONOLACTONE;

ALGORITHM; ASSISTED CIRCULATION; CARDIAC RESYNCHRONIZATION THERAPY; DEFIBRILLATOR; DRUG EFFICACY; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART STIMULATION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; REVIEW;

EID: 1342333334     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.4-1-18     Document Type: Review

References (34)

1. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325:293-302.
2. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-35.
3. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992;327: 685-91. Erratum: N Engl J Med 1992;327: 1768.
4. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992;327: 685-91. Erratum: N Engl J Med 1992;327: 1768.
5. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-11): a randomised trial. Lancet 1999;353:9-13.
6. Packer M, Coats AJ, Fowler MB, Katus HA et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
7. Packer M, Bristow MR, Cohn JN, Colucci WS et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334:1349-55.
8. Olsen SL, Gilbert EM, Renlund DG, Taylor DO et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995;25:1225-31.
9. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. Circulation 1995;92:212-8.
10. Bristow MR, Gilbert EM, Abraham WT, Adams KF et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996;94:2807-16.
11. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353: 2001-7.
12. Pitt B, Zannad F, Remme WJ, Cody R et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-17.
13. Pitt B, Remme W, Zannad F, Neaton J et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
14. McMurray JJ, Ostergren J, Swedberg K, Granger CB et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.
15. Cohn JN, Johnson G, Ziesche S, Cobb F et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of patients with chronic congestive heart failure. N Engl J Med 1991;325: 303-10.
16. Cohn JN, Archibald DG, Ziesche S, Franciosa JA et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-52.
17. Neuberg GW, Miller AB, O'Connor CM, Belkin R et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002;144:31-8.
18. Batin P, Wickens M, McEntegart D, Fullwood L, Cowley AJ. The importance of abnormalities of liver function tests in predicting mortality in chronic heart failure. Eur Heart J 1995;16:1613-8.
19. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997;336:525-33.
20. Packer M, Gheorghiade M, Young JB, Costantini PJ et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993;329:1-7.
21. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002;347:1403-11.
22. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289:871-8.
23. Anker SD, Clark AL, Kilowski C, Zugck C et al. Statins and survival in 2068 CHF patients with ischemic and non-ischemic etiology. Circulation 2002;106:2535A.
24. Struthers AD, Donnan PT, Lindsay P, McNaughton D et al. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 2002;87:229-34.
25. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12065 patients with new-onset heart failure. Circulation 2003; 107:223-5.
26. Silverberg DS, Wexler D, Sheps D, Blum M et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001;37:1775-80.
27. Guillo P, Mansourati J, Maheu B, Etienne Y et al. Long-term prognosis in patients with alcoholic cardiomyopathy and severe heart failure after total abstinence. Am J Cardiol 1997;79:1276-8.
28. Belardinelli R, Georgiou D, Cianci G, Purcaro A. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation 1999;99:1173-82.
29. Opasich C, Febo O, Riccardi PG, Traversi E et al. Concomitant factors of decompensation in chronic heart failure. Am J Cardiol 1996;78:354-7.
30. Moss AJ, Zareba W, Hall WJ, Klein H et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
31. Cleland JG, Daubert JC, Erdmann E, Freemantle N et al. The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end-points. Eur J Heart Fail 2001;3:481-9.
32. Feldman AM, Bristow MR. The Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. Am Coll Cardiol 2003;Scientific Sessions.
33. Aaronson KD, Patel H, Pagani FD. Patient selection for left ventricular assist device therapy. Review. Ann Thorac Surg 2003; 75(6 Suppl):S29-35.
34. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: seventeenth official report-2000. J Heart Lung Transplant 2000; 19:909-31.